Vertex Pharmaceuticals Incorporated and Genomics plc announced a three-year collaboration (extendable to five years) to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and patient stratification in diseases with significant unmet need.
Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.
BOSTON–(BUSINESS WIRE)–Health Connexions™ announced today a collaborative partnership with Genelle, a genetic wellness company that provides the opportunity for consumers to unlock their potential through Predictive Consumer Genomics and customized […]
GlaxoSmithKline wants to better understand biology so it can discover more medicines, like every other drugmaker. It also wants to quit wasting money on drug candidates that look promising in […]
While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of hurdles that are impeding more rapid market uptake, […]
